Interestingly, this effect was mediated by the release of CCK and GLP-1 and subsequent activation of their receptors, possibly on VANs (see Hormonal gut-brain signaling section)
More serious considerations the evaluating clinician will screen for include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (GLP-1 medications carry a boxed warning for thyroid C-cell tumors based on animal studies), a history of pancreatitis, gallbladder disease, and severe gastrointestinal conditions
This gut-first approach makes it appealing to those who want a sustainable, non-invasive alternative to prescription medications
The legal status of compounded GLP-1 medications depends on shortage designations
Song E, Su C, Fu J, Xia X, Yang S, Xiao C et al